Thor Medical ASA Unveils Strategic Vision for Next-Gen Cancer Treatments at 2024 Capital Markets Update
Thor Medical ASA Vision and Highlights for 2024
Company Overview
Thor Medical ASA (Oslo Børs: TRMED) is focused on supplying alpha-emitters for cancer treatment. The company aims to lead in this market and presented its vision and strategy during a Capital Markets Update (CMU) in Stockholm.
CEO Statement
CEO Jasper Kurth stated, “Thor Medical plans to be a top supplier of alpha-emitters for cancer therapies. This year, we made significant strides. The number of clinical trials in radiopharmaceuticals is at a record high. Successful product launches will increase demand for our isotopes: Thorium-228, Radium-224, and Pb-212. We are entering a new era in cancer treatment with precision therapies.”
Key Highlights for 2024
- Completed pilot facilities at Herøya on schedule and within budget.
- Secured a five-year supply agreement with ARTBIO for Thorium-228.
- Shipped the first batch of Thorium-228 from the new facilities.
- Signed a three-year supply agreement with a leading pharmaceutical company for Pb-212.
- Established strong partnerships with suppliers to ensure a steady supply of raw materials.
- Finished a concept study for the ‘AlphaOne’ commercial plant, estimated to require USD 30 million.
Event Details
The CMU takes place at Carnegie’s premises in Stockholm. Attendees can join in person or via a live webcast.
- Date & Time: 25 November 2024, from 13:00 to 15:00 CET
- Location: Regeringsgatan 56, 111 56 Stockholm
- Registration Link: Join the Webcast
Agenda Highlights
- Introduction by Jasper Kurth, CEO of Thor Medical
- Presentation on Targeted Alpha Therapies by Professor Jane Sosabowski, PhD
- Discussion on Isotope Supply by Emanuele Ostuni, PhD, CEO of ARTBIO
- Presentation on Thor Medical’s role in precision cancer treatments by Jasper Kurth and Brede Ellingsæter, CFO
Audience Interaction
The event will allow questions from both live and online participants.